Join to View Full Profile
44 Binney St# D1B22Boston, MA 02115
Phone+1 617-632-2949
Fax+1 617-632-5168
Dr. Koreth is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2004- Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2000
Maulana Azad Medical CollegeClass of 1993
Certifications & Licensure
CA State Medical License 2008 - Present
MA State Medical License 2001 - 2026
ME State Medical License 2022 - 2025
American Board of Internal Medicine Hematology
Clinical Trials
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
- Ultra-Low Dose Interleukin-2 for Refractory Chronic Graft Versus Host Disease Start of enrollment: 2007 Aug 01
- Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies Start of enrollment: 2007 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Toward Improving Initial Therapy of Acute Graft Versus Host Disease.Ansh Krishnachandra Mehta, John Koreth
American Journal of Hematology. 2025-05-01 - First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer.Roman M Shapiro, Michal Sheffer, Matthew A Booker, Michael Y Tolstorukov, Grace C Birch
Journal of Hematology & Oncology. 2025-02-14 - 3 citationsNon-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR NK cell responses.Shaobo Yang, Michal Sheffer, Isabel E Kaplan, Zongqi Wang, Mubin Tarannum
Nature Biotechnology. 2024-10-04
Journal Articles
- Small-Molecule BCL6 Inhibitor Effectively Treats Mice with Non-Sclerodermatous Chronic Graft-Versus-Host DiseaseJoseph H Antin, Bruce Blazar, Leo Luznik, John Koreth, Ivan Maillard, Robert J Soiffer, James E Bradner, Jonathan S Serody, Jerome Ritz, Blood
Press Mentions
Equillium Announces Positive Topline Results from the EQUATE Study in First-Line Treatment of Acute Graft-Versus-Host DiseaseJune 11th, 2021- Equillium Announces Oral Presentation Highlighting Positive Data from the EQUATE Study in Acute Graft-Versus-Host Disease at the EHA2021 Virtual Congress of the European Hematology AssociationMay 13th, 2021
- Equillium Presents Positive Interim Clinical Data of Itolizumab in First-Line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital ExperienceFebruary 12th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
